RTTNews | Sep 9, 2021 08:25AM EDT

08:25 Thursday, September 9, 2021 (RTTNews.com) - Soligenix, Inc. (SNGX) said the Office of Orphan Products Development of FDA has granted orphan drug designation to the active ingredient hypericin for the treatment of T-cell lymphoma, extending the target population beyond cutaneous T-cell lymphoma.

"The FDA's decision to grant and expand our hypericin orphan drug designation beyond cutaneous T-cell lymphoma signifies an important step for Soligenix as we continue to advance the program toward NDA filing in the first half of 2022," said Christopher Schaber, President & Chief Executive Officer of Soligenix.

Shares of Soligenix were up 17% in pre-market trade on Thursday.

Read the original article on RTTNews ( https://www.rttnews.com/3224483/soligenix-reports-extension-of-hypericin-orphan-designation-beyond-cutaneous-t-cell-lymphoma.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved